<DOC>
	<DOC>NCT02434484</DOC>
	<brief_summary>This is a PMS of Symbenda Injection (bendamustine hydrochloride) in Korean Patients. The main objective is to obtain safety information related to Symbenda treatment from clinical practice.</brief_summary>
	<brief_title>Symbenda Post-Marketing Surveillance (PMS)</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda will be enrolled in the study. This study will be conducted as complete surveillance method; subjects who meet the inclusion/exclusion criteria and administrate Symbenda for the first time after conclusion of agreement will be enrolled. Patients who meet the following criteria will be eligible for inclusion in the study: 1. Patients with approved indication for Symbenda in Korea 2. Patients who have verbal or written consent for use of personal and medical information for the study purpose Investigators will refer to approved indications and contraindications regarding inclusion criteria. Investigators will refer to approved indications and contraindications regarding exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Symbenda</keyword>
	<keyword>Non-Hodgkin's lymphomas</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Bendamustine Hydrochloride</keyword>
</DOC>